The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

Cellis is preparing to take its lead candidate into the clinic after seeing durable complete remissions in solid-tumor models. Drug developers have struggled to translate the exceptional efficacy ...

A new study from Cornell University has strengthened the case for using a specific group of molecules—known as microRNAs—as ...

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more ...

Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In animal models, combining macbecin II with immunotherapies, including ...

Drugs and other treatments can be quite effective at killing cancer cells, yet many fall short as they struggle to penetrate ...

Mathematical models for predicting how cancer tumors in mice grow over time can give distorted results if unmeasurable data ...

Aptevo Therapeutics (APVO) provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the ...

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a ...

Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...